Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Assets (2016 - 2025)

Historic Current Assets for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $229.4 million.

  • Heron Therapeutics' Current Assets rose 1752.83% to $229.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.4 million, marking a year-over-year increase of 1752.83%. This contributed to the annual value of $209.0 million for FY2024, which is 1072.18% up from last year.
  • Heron Therapeutics' Current Assets amounted to $229.4 million in Q3 2025, which was up 1752.83% from $210.9 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Current Assets high stood at $366.8 million for Q2 2021, and its period low was $165.3 million during Q2 2023.
  • Its 5-year average for Current Assets is $221.9 million, with a median of $209.0 million in 2024.
  • As far as peak fluctuations go, Heron Therapeutics' Current Assets tumbled by 4705.69% in 2022, and later skyrocketed by 1752.83% in 2025.
  • Heron Therapeutics' Current Assets (Quarter) stood at $254.4 million in 2021, then decreased by 19.25% to $205.4 million in 2022, then decreased by 8.11% to $188.8 million in 2023, then rose by 10.72% to $209.0 million in 2024, then grew by 9.75% to $229.4 million in 2025.
  • Its Current Assets stands at $229.4 million for Q3 2025, versus $210.9 million for Q2 2025 and $212.8 million for Q1 2025.